Biolife solutions collaborates with seattle children's to improve viral vector and cell and gene therapy manufacturing

Bothell, wash., jan. 4, 2022 /prnewswire/ -- biolife solutions, inc. (nasdaq: blfs), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapy and broader biopharma markets, today announced an extended collaboration with seattle children's therapeutics, a venture at seattle children's, bringing cutting edge, curative technologies and therapies to defeat pediatric cancer and other diseases that impact children.
BLFS Ratings Summary
BLFS Quant Ranking